Causaly, an AI startup helping with preclinical discovery, nabs $60M from VCs and former J&J chief Alex Gorsky
The AI hype isn’t letting up: Another startup in the preclinical discovery world has reeled in a fresh $60 million, including investment from Johnson & Johnson’s former chair and CEO Alex Gorsky.
London and San Francisco company Causaly disclosed its Series B Thursday morning, saying it now serves 12 of the top 20 pharma companies. Gilead, Novo Nordisk, Regeneron and the FDA are among its customers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.